COVID-19 Omicron: what it is, how it behaves, and how it compares to earlier variants

Omicron refers to the SARS‑CoV‑2 variant lineage B.1.1.529 and its numerous subvariants, first detected in southern Africa in late 2021 and designated a variant of concern by the WHO on 26 November 2021. This variant is defined by a large set of spike protein mutations, some of which alter receptor binding and immune evasion, contributing to high transmissibility and increased risk of reinfection relative to earlier variants. Omicron rapidly became the globally dominant lineage, leading to substantial waves of infection. This overview explains what Omicron is, how it behaves, how it compares to prior variants, and the implications for vaccines, tests, treatments, and public health measures.

What Omicron is and where it emerged

Omicron is a lineage of SARS‑CoV‑2, the virus that causes COVID‑19, first reported to the WHO on 24 November 2021 after cases were identified in South Africa. It is one of the most genetically changed variants, with dozens of mutations in the spike protein alone, including in the receptor‑binding domain. The variant was designated a variant of interest (VOI) on 26 November 2021 and a variant of concern (VOC) shortly thereafter. Its emergence exemplifies viral evolution under population immunity and selection pressure. Omicron encompasses a broad family of subvariants, such as BA.1, BA.2, BA.4, BA.5, XBB, and later descendants, each with further spike changes. Because of its evolutionary distance from early pandemic strains, Omicron raised concerns about diagnostic accuracy, vaccine matching, and the durability of immunity from infection or vaccination.

How Omicron behaves and spreads

Omicron is markedly more transmissible than previous variants such as Delta. This increased transmissibility stems from a combination of immune escape, allowing reinfections and some breakthrough infections in vaccinated individuals, and higher intrinsic replicative fitness in human cells. The incubation period remains similar to other variants—typically 2–5 days—but the generation time may be shorter, facilitating rapid epidemic growth. Omicron replicates efficiently in the upper respiratory tract and can evade preexisting neutralizing antibodies, particularly when immunity wanes or vaccine doses are not recent. However, current evidence suggests that prior infection or vaccination still provides meaningful protection against severe disease, albeit reduced compared to earlier variants. Community transmission during the Omicron period frequently led to high case counts even in populations with substantial prior immunity, highlighting the importance of layered prevention strategies.

Symptom profile and clinical severity

Typical signs and reported experiences

While Omicron can cause the full spectrum of COVID-19 illness, clinical findings and patient reports indicate certain patterns are common. Symptoms often resemble those of other respiratory viral illnesses and may include sore throat, rhinorrhea, cough, fatigue, headache, and fever. Loss of smell or taste, while possible, appears less consistently reported with Omicron compared to earlier waves. Shortness of breath and clinical pneumonia are less common in vaccinated or previously infected individuals but can occur, particularly in those without protection or with risk factors. Most people experience mild to moderate illness and recover without medical care. However, vulnerable populations—including older adults and those with certain underlying conditions—are at higher risk of severe outcomes. Monitoring in multiple countries has shown that case severity decreased with successive waves during the Omicron period, though absolute numbers of hospitalizations remain substantial due to the very high case incidence.

Population-level impact and outcomes

Omicron waves produced sharp increases in case counts globally, often with different timing across regions due to factors like population immunity, prior waves, vaccine coverage, and public health measures. The overall severity at the population level was modified by vaccination status, age structure, and the circulation of preexisting immunity from infection. Compared with earlier variants, Omicron has been associated with a lower risk of hospitalization and death per infection, but the sheer number of infections has still resulted in many hospitalizations and deaths. Key factors include vaccine effectiveness against infection waning over time, the emergence of subvariants with additional immune-evolving mutations, and the protection conferred by recent infection. Public health agencies continue to track severity trends, healthcare system capacity, and long‑term sequelae (often called long COVID), though population-level burden remains substantial due to case volume. The variant also underscored the importance of genomic surveillance to detect changes in transmissibility, immune escape, and vaccine match.

Vaccines, boosters, and immune protection

Effectiveness against infection, severe disease, and waning

Vaccines remain a cornerstone of reducing severe disease and death from Omicron. Primary series and booster doses restore neutralizing antibody levels that had waned and broaden cellular immunity, leading to improved protection against hospitalization and death. However, vaccine effectiveness against symptomatic infection declines more rapidly with Omicron than with earlier variants, and two doses without a booster are associated with reduced protection. Additional boosters, particularly with updated formulations targeting circulating variants, have improved protection, though gains are often temporary and decline over months. Immunocompromised individuals and older populations may have a lower immunologic response to vaccination, warranting additional recommended doses. Overall, vaccination and timely boosters substantially reduce the risk of severe outcomes, even when breakthrough infections occur, making vaccination a durable public health tool.

Tests, treatments, and public health tools

Diagnostics, antiviral therapies, and layered prevention

Omicron generally behaves similarly to other variants in terms of diagnostic detection. Antigen rapid tests and PCR assays remain effective, though the timing of viral shedding and test sensitivity can vary, and some home tests may show slightly reduced sensitivity during early infection. Several antiviral treatments, including nirmatrelvir/ritonavir and remdesivir, remain effective against Omicron when started early in at-risk individuals. Monoclonal antibody therapies that were used earlier in the pandemic have largely lost neutralizing activity against Omicron due to spike changes. Non-pharmaceutical interventions—masking, improved ventilation, testing, isolation, and strategic use of pre-event testing—remain valuable tools to reduce transmission, especially during periods of high community levels. Layered approaches tailored to local epidemiology and individual risk are recommended, alongside the availability of updated vaccines and clinical guidance on prioritizing treatment for those at highest risk.

Comparison with earlier variants

Omicron differs from earlier variants such as Alpha, Gamma, and Delta in several key respects. Its spike protein contains numerous mutations that enhance immune escape and facilitate rapid spread, making it the most transmissible variant to date. Compared with Delta, Omicron causes a lower risk of hospitalization and mortality per infection, but its extremely high transmissibility has still led to substantial absolute numbers of severe cases. Earlier variants generally showed less ability to rein infect individuals with preexisting immunity, whereas Omicron frequently causes reinfections. The clinical syndrome associated with Omicron tends to involve upper respiratory symptoms more prominently, though the overall spectrum of illness remains broad. These differences highlight the importance of continued genomic surveillance, updated vaccines, and adaptable public health strategies as the virus evolves.

Key facts at a glance

Definitions and context

• Variant of concern (VOC): A variant with evidence of increased transmissibility, virulence, or reduced public health effectiveness.
• Immune escape: The ability of a variant to partially evade preexisting neutralizing antibodies from infection or vaccination.
• Subvariant: A descendant lineage that carries additional mutations (e.g., BA.5, XBB.1.5 within the Omicron family).
• Case severity: The clinical outcome for an individual, which is influenced by vaccination, prior infection, age, and underlying conditions.
• Incubation period: The time between exposure and symptom onset; for SARS‑CoV‑2 it is typically a few days.
• R0 (basic reproduction number): An approximate measure of average secondary infections from one case in a fully susceptible population.

Bottom line

Omicron is a heavily mutated SARS‑CoV‑2 variant that is more transmissible than earlier lineages and better at evading prior immunity. While vaccines and boosters lower the risk of severe outcomes, protection against infection wanes over time. Omicron’s clinical severity is generally lower per infection, but population-level impact remains considerable due to very high case incidence. Continued genomic surveillance, updated vaccines, layered prevention, and early treatment for at‑risk individuals are key components of an effective, enduring response.